The European Association of Euro-Pharmaceutical Companies, whichrepresents parallel importers operating in the European Union/European Economic Area, has been discussing industry concerns over the potential for parallel trade in manufacturers' charitable or cut-price supply of drugs to countries which could not otherwise afford them.
"The EAEPC is happy to confirm that, in cases where medicines, vaccines or similar health care items are offered for humanitarian purposes to governments of developing countries on differentially favorable terms, none of its members will ever be party to any attempt to acquire or re-sell the products concerned," the group says in statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze